U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H24N2O5
Molecular Weight 396.4364
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BENAZEPRILAT

SMILES

OC(=O)CN1C2=CC=CC=C2CC[C@H](N[C@@H](CCC3=CC=CC=C3)C(O)=O)C1=O

InChI

InChIKey=MADRIHWFJGRSBP-ROUUACIJSA-N
InChI=1S/C22H24N2O5/c25-20(26)14-24-19-9-5-4-8-16(19)11-13-17(21(24)27)23-18(22(28)29)12-10-15-6-2-1-3-7-15/h1-9,17-18,23H,10-14H2,(H,25,26)(H,28,29)/t17-,18-/m0/s1

HIDE SMILES / InChI
Molecular Formula C22H24N2O5
Molecular Weight 396.4364
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/pro/benazepril.html | DOI: 10.1111/j.1527-3466.1990.tb00432.x

BENAZEPRIL, (±)- is an impurity referred to as Related Compound B, which is a diastereomer of benazepril, an ACE inhibitor, under the brand name Lotensin used primarily in treatment of hypertension, congestive heart failure, and heart attacks, and also in preventing the renal and retinal complications of diabetes. BENAZEPRIL, (±)- is used as USP Reference Standard.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Benazepril crossed the blood-brain barrier only to an extremely low extent.

Originator

Approval Year

1991
122
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 14.0 nM [IC50]
Inhibitor
8504
 0.1 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
LOTENSIN

Approved Use

Amlodipine besylate and benazepril hydrochloride capsules is a combination capsule of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB) and benazepril, an angiotensin converting enzyme (ACE) inhibitor. Amlodipine besylate and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent (1) 1.1 Hypertension Amlodipine besylate and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent.

Launch Date

1991
Primary
Approved
8583
BENAZEPRIL HYDROCHLORIDE

Approved Use

Benazepril hydrochloride tablets are indicated for the treatment of hypertension. They may be used alone or in combination with thiazide diuretics.

Launch Date

1991
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
437 pmol/g
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2344861
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BENAZEPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
334 pmol × h/g
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2344861
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BENAZEPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.6 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2344861
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BENAZEPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Other AEs: Headache, Back pain...
Other AEs:
Headache (8.6%)
Back pain (2.6%)
Diarrhoea (0.9%)
Upper respiratory tract infection (3.4%)
Peripheral oedema (1.7%)
Sinusitis (1.7%)
Fatigue (0.9%)
Cough (1.7%)
Arthralgia (0.9%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Other AEs: Headache, Fatigue...
Other AEs:
Headache (9%)
Fatigue (2%)
Nausea (2%)
Dizziness (2%)
Cough increased (2%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Other AEs: Headache, Fatigue...
Other AEs:
Headache (3%)
Fatigue (2%)
Nausea (1%)
Dizziness (3%)
Dizziness postural (1%)
Cough increased (2%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Other AEs: Headache, Fatigue...
Other AEs:
Headache (3%)
Fatigue (2%)
Nausea (1%)
Dizziness (2%)
Dizziness postural (1%)
Cough increased (1%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Other AEs: Headache, Dizziness...
Other AEs:
Headache (6%)
Dizziness (2%)
Dizziness postural (2%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Other AEs: Headache, Fatigue...
Other AEs:
Headache (2%)
Fatigue (5%)
Nausea (1%)
Cough increased (1%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
AEs

AEs

AESignificanceDosePopulation
Arthralgia 0.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Diarrhoea 0.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Fatigue 0.9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Cough 1.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Peripheral oedema 1.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Sinusitis 1.7%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Back pain 2.6%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Upper respiratory tract infection 3.4%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Headache 8.6%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://pubmed.ncbi.nlm.nih.gov/11464260/
Cough increased 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Dizziness 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Fatigue 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Nausea 2%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Headache 9%
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Dizziness postural 1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Nausea 1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Cough increased 2%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Fatigue 2%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Dizziness 3%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Headache 3%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Cough increased 1%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Dizziness postural 1%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Nausea 1%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Dizziness 2%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Fatigue 2%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Headache 3%
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Dizziness postural 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Dizziness 2%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Headache 6%
5 mg 1 times / day multiple, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Cough increased 1%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Nausea 1%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Headache 2%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Fatigue 5%
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
unhealthy
Health Status: unhealthy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1893640/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
OATP1B1
1079
PEPT1
60

CES1
45
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
OATP1B1
1095
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CES1
45
 yes
PEPT1
60
 yes
PubMed

PubMed

TitleDatePubMed
Effects of co-administration of urokinase and benazepril on severe IgA nephropathy.
2004-04
Hypertensive patients from two rural Chinese counties respond differently to benazepril: the Anhui Hypertension Health Care Study.
2004-02
Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress.
2004-02
Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis.
2004-02
Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus.
2004-01-13
Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass.
2004-01
Systemic contact dermatitis due to captopril without cross-sensitivity to fosinopril, quinapril and benazepril.
2004
Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy.
2003-12-23
Gene expression profile revealed different effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibitor on heart failure.
2003-12
Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients.
2003-11
[Vasopressin analogue injection as ultimate measure for counteracting severe catecholamine-refractory poisoning by several vasodilators taken with suicidal intent].
2003-10-17
Investigation of pimobendan versus benazepril in canine myxomatous valvular disease.
2003-10-04
By the way, doctor. After a recent blood pressure check, my doctor bumped up my dose of Lotensin [an ACE inhibitor] from 10 milligrams to 20. I had been taking the 10-mg pill in the morning, but my doctor advised me to take the new, higher dose in the evening. He said most strokes and heart attacks happen in the morning, and that I could get better protection by taking the drug right before. But I read in the Health Letter a couple of months ago that you recommend morning intake, so I am confused.
2003-10
Angiotensin II inhibition increases cellular glucose transport during reperfusion but not ischemia in pig hearts.
2003-09
The first hypertension trial comparing the effects of two fixed-dose combination therapy regimens on cardiovascular events: Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH).
2003-08-28
Rationale for combination therapy as initial treatment for hypertension.
2003-08-28
Using the electronic medical record to enhance the use of combination drugs.
2003-08-26
Sialic acid 9-O-acetylesterase catalyzes the hydrolyzing reaction from alacepril to deacetylalacepril.
2003-08
Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients.
2003-08
Argyria associated with colloidal silver supplementation.
2003-07
Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches.
2003-06-27
An angiotensin converting enzyme inhibitor, benazepril can be transformed to an active metabolite, benazeprilat, by the liver of dogs with ascitic pulmonary heartworm disease.
2003-06
Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting.
2003-06
[Study on candidate genes of benazepril related cough in Chinese hypertensives].
2003-06
Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats.
2003-06
[Postmarketing surveillance of benazepril-related cough and related risk factors analysis on hypertensives].
2003-05
Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension.
2003-04
Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
2003-04
Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.
2003-03
Correlation of Angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by Angiotensin-converting enzyme inhibitor.
2003-03
Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.
2003-03
Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients.
2003-03
[Effect of the compound of traditional Chinese drugs on gene expression of renal endothelin and its receptor of experimental diabetic nephropathy].
2003-02
Linear IgA dermatosis induced by a new angiotensin-converting enzyme inhibitor.
2003-02
Quantitative determination of benazepril and benazeprilat in human plasma by gas chromatography-mass spectrometry using automated 96-well disk plate solid-phase extraction for sample preparation.
2003-01-05
Effects of antihypertensive drugs on peritoneal vessels in hypertensive dogs with mild renal insufficiency.
2003
ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control.
2003
[The use of angiotensin-converting enzyme inhibitor benazepril in acute period of myocardial infarction].
2003
[Comparative effectiveness of lotensin and capoten in patients with chronic cardiac failure].
2003
Optimisation by experimental design of a capillary electrophoretic method for the separation of several inhibitors of angiotensin-converting enzyme using alkylsulphonates.
2002-11-29
Reoptimization of MDL keys for use in drug discovery.
2002-11-26
[Non-immunologic factor: immunosuppressive drug-induced nephrotoxicity].
2002-11
The effects of antihypertensive agents on the survival rate of polycystic kidney disease in Han:SPRD rats.
2002-11
Selection of the dose of angiotensin converting enzyme inhibitor for patients with diabetic nephropathy depends on the presence or absence of left ventricular hypertrophy.
2002-11
[Effects of benazepril on apoptosis in the kidney of diabetic rats].
2002-06
[Clinical observation on effect of shenle capsule in treating mesangial proliferating glomerulonephritis].
2002-05
[CEA comprehensive evaluation for Western and traditional Chinese hypotensive drugs].
2001-09
[Serological study on inhibitory function of shenkang injection on glomerular mesangial cell].
2001-07
Short-term metabolic effects of the ACE-inhibitor benazepril in type 2 diabetes mellitus associated with arterial hypertension.
1992-07-01
Sympathomoderating influence of benazepril in essential hypertension.
1992-04
Patents

Patents

08173840
4
08617587
4
JP2002322064A
4
JP2002535367A
25
JP2002536332A
39
JP2002538172A
23
JP2002541106A
100
JP2002541233A
406
JP2003503381A
36
JP2003508349A
46
JP2003515526A
470
JP2005041875A
13
JP2005526756A
4
JP2005527462A
22
JP2007520453A
36
JP2007524644A
51
JP2009102441A
4
JP2009526755A
475
JP2010043111A
14
JP2011506455A
52
JP2011510067A
60
JP2011510954A
147
JP2011524416A
146
JP4606172B2
29
JP4705912B2
48
JP4722295B2
105
JPH02121922A
14
JPH107566A
5
US4410520
4
WO2006084761A1
4

Sample Use Guides

In Vivo Use Guide
The recommended initial dose for patients not receiving a diuretic is 10 mg once a day. The usual maintenance dosage range is 20-40 mg per day administered as a single dose or in two equally divided doses. A dose of 80 mg gives an increased response, but experience with this dose is limited.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: In the isolated rabbit aorta the vasocontraction induced by PGF2 alpha was competitively antagonized at 10(-5)-10(-4) mol/l, while vascular responses induced by PGE1, PGE2 or PGI2 was inhibited at 3 x 10(-4) mol/l of benazepril. https://www.ncbi.nlm.nih.gov/pubmed/2080946
Benazepril inhibited both adrenaline-stimulated aortic PGI2 synthesis (25 pg mg -1 min-1) and carbachol-stimulated urinary bladder PGI2 synthesis (20 pg mg -1 min-1) in dose-dependent manners. IC50 (concentrations of antagonist at which agonist-stimulated PGI2 synthesis was inhibited by 50%) was 8 x 10-5.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:31:26 GMT 2025
Edited
by admin
on Mon Mar 31 18:31:26 GMT 2025
Record UNII
JRM708L703
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BENAZEPRIL RELATED COMPOUND C
USP   USP-RS  
Preferred Name English
BENAZEPRILAT
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
Benazeprilat [WHO-DD]
Common Name English
BENAZEPRILAT [USAN]
Common Name English
benazeprilat [INN]
Common Name English
1H-1-BENZAZEPINE-1-ACETIC ACID, 3-((1-CARBOXY-3-PHENYLPROPYL)AMINO)-2,3,4,5-TETRAHYDRO-2-OXO-, (S-(R*,R*))-
Common Name English
CGS-14831
Code English
BENAZEPRIL DIACID
MI  
Common Name English
BENAZEPRIL HYDROCHLORIDE IMPURITY C [EP IMPURITY]
Common Name English
BENAZEPRIL DIACID [MI]
Common Name English
BENAZEPRIL RELATED COMPOUND C [USP IMPURITY]
Common Name English
CGS 14831
Code English
(3S)-3-[[(1S)-1-Carboxy-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid
Systematic Name English
BENAZEPRIL RELATED COMPOUND C [USP-RS]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175562
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
NCI_THESAURUS C247
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
Code System Code Type Description
IUPHAR
6375
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
NDF-RT
N0000178477
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY Decreased Blood Pressure [PE]
CHEBI
88200
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
EPA CompTox
DTXSID501024701
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
SMS_ID
100000086591
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
INN
6128
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
MERCK INDEX
m2303
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY Merck Index
EVMPD
SUB05701MIG
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
NCI_THESAURUS
C72907
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
DRUG BANK
DB14125
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
FDA UNII
JRM708L703
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
PUBCHEM
5463984
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
RXCUI
1546196
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY RxNorm
CAS
86541-78-8
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
DAILYMED
JRM708L703
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
USAN
Y-90
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
RS_ITEM_NUM
1048641
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
ChEMBL
CHEMBL1192519
Created by admin on Mon Mar 31 18:31:26 GMT 2025 , Edited by admin on Mon Mar 31 18:31:26 GMT 2025
PRIMARY
Related Record Type Details
ANGIOTENSIN-CONVERTING ENZYME
TARGET -> INHIBITOR
Related Record Type Details
Structure of BENAZEPRIL
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
Structure of BENAZEPRIL HYDROCHLORIDE
PARENT -> IMPURITY
Related Record Type Details
Structure of BENAZEPRILAT
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966